Figure 2
Figure 2. Apcmin bone marrow has enhanced repopulating potential. (A) Whole-blood chimerism (expressed as the fraction of CD45.2-positive donor cells divided by CD45.2 and CD45.1/2 competitor cells) 16 weeks after transplantation into lethally irradiated 45.1 recipients. Representative data of 2 independent experiments. Apcmin 73.1% versus WT 55.9% chimerism, P = .001 (B) Whole-blood chimerism of transplant recipients at 4, 8, and 16 weeks after transplantation. Mean ± SEM (C) Bone marrow chimerism, gated on LKS+ cells 16 weeks after transplantation into lethally irradiated recipients. Apcmin 79.8% versus 58.2% WT, P = .015

Apcmin bone marrow has enhanced repopulating potential. (A) Whole-blood chimerism (expressed as the fraction of CD45.2-positive donor cells divided by CD45.2 and CD45.1/2 competitor cells) 16 weeks after transplantation into lethally irradiated 45.1 recipients. Representative data of 2 independent experiments. Apcmin 73.1% versus WT 55.9% chimerism, P = .001 (B) Whole-blood chimerism of transplant recipients at 4, 8, and 16 weeks after transplantation. Mean ± SEM (C) Bone marrow chimerism, gated on LKS+ cells 16 weeks after transplantation into lethally irradiated recipients. Apcmin 79.8% versus 58.2% WT, P = .015

Close Modal

or Create an Account

Close Modal
Close Modal